ArticleAnnals of laboratory medicine2017
Fecal Calprotectin Level Reflects the Severity of Clostridium difficile Infection.
Article in Annals of laboratory medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04491799 (Fecal Calprotectin Level in Differentiating Between Inflammatory and Non-inflammatory Diarrhea in Patients With Nosocomial Diarrhea), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fecal Calprotectin Level in Differentiating Between Inflammatory and Non-inflammatory Diarrhea in Patients With Nosocomial Diarrhea
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- The value of fecal calprotectin inFrontiers in physiology · 2022Pooled it
- Trial
- Diagnosis ofJournal of medical microbiology · 2024Review
- Review
- "Antibiotics (Basel, Switzerland) · 2024Article
- Predictive value of fecal calprotectin and lactoferrin levels for negative outcomes in Clostridioides difficile infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Advances in diagnostic assays forFrontiers in cellular and infection microbiology · 2024Review
- Diagnostic Guidance for C. difficile Infections.Advances in experimental medicine and biology · 2024Article
- Stool Interleukin-1β Differentiates Clostridioides difficile Infection (CDI) From Asymptomatic Carriage and Non-CDI Diarrhea.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Microbiome profile and calprotectin levels as markers of risk of recurrentFrontiers in cellular and infection microbiology · 2023Article
- Usefulness of Fecal Calprotectin in the Management of Patients with ToxigenicJournal of clinical medicine · 2021Article
- Article
- Defining the black box: a narrative review of factors associated with adverse outcomes from severeTherapeutic advances in gastroenterology · 2021Review
- Usefulness of Testing for Fecal Calprotectin in Pediatric Gastroenterology Clinical Practice.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Review
- Relationship between faecal metronidazole and lactoferrin concentrations to clinical response of patients with Clostridioides difficile.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Investigation of Intestinal Microbiota and Fecal Calprotectin in Non-Toxigenic and ToxigenicMicroorganisms · 2020Article
- ZupT Facilitates Clostridioides difficile Resistance to Host-Mediated Nutritional Immunity.mSphere · 2020Article
- The xenobiotic sensing pregnane X receptor regulates tissue damage and inflammation triggered by C difficile toxins.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Anti-inflammatory Gut Microbial Pathways Are Decreased During Crohn's Disease Exacerbations.Journal of Crohn's & colitis · 2019Article
- Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile is a significant nosocomial and community-acquired pathogen, and is the leading cause of antibiotic-induced diarrhea associated with high morbidity and mortality. Given that the treatment outcome depends on the severity of C. difficile infection (CDI), we aimed to establish an efficient method of assessing severity, and focused on the stool biomarker fecal calprotectin (FC). FC directly reflects the intestinal inflammation status of a patient, and can aid in interpreting the current guidelines, which requires the integration of indirect laboratory parameters. The distinction of 80 patients with CDI versus 71 healthy controls and 30 severe infection cases versus 50 mild cases was possible using FC as a marker. The area under the receiver operating characteristic curves were 0.821 and 0.746 with a sensitivity of 75% and 70% and specificity of 79% and 80%, for severe versus mild cases, respectively. We suggest FC as a predictive marker for assessing CDI severity, which is expected to improve the clinical management of CDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.